XNAS · Healthcare · Biotechnology
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.96 | -0.63 | +34.38% | $0 | ✅ Beat | +0.70% | +4.17% | — |
| 2026-05-07 | Q1 2026 | -0.68 | -0.95 | -39.71% | $0 | ❌ Miss | -3.55% | +0.00% | -4.40% |
| 2026-03-10 |
| Q4 2025 |
| -1.27 |
| -6.73 |
| -429.92% |
| $0 |
| ❌ Miss |
| +0.68% |
| -0.82% |
| -21.75% |
| 2025-11-12 | Q3 2025 | -1.19 | -2.91 | -144.54% | $0 | ❌ Miss | — | — | — |
Showing last 4 quarters.